化合物KY-226
| 中文名稱 | 化合物KY-226 |
|---|---|
| 中文同義詞 | 化合物KY-226;化合物KY-226,10 MM DMSO 溶液;4-((([1,1'-聯(lián)苯]-4-基甲基)硫代)甲基) -N-(己基磺酰基)苯甲酰胺 |
| 英文名稱 | KY-226 |
| 英文同義詞 | KY-226;Benzamide, 4-[[([1,1'-biphenyl]-4-ylmethyl)thio]methyl]-N-(hexylsulfonyl)-;4-[[([1,1'-Biphenyl]-4-ylmethyl)thio]methyl]-N-(hexylsulfonyl)benzamide;inhibit,anti-diabetic,leptin,ZO-1,LPS,insulin,phosphorylated,KY-226,Akt,KY226,anti-obesity,PTP1B,Phosphatase,neurons,Inhibitor,KY 226;KY-226, 10 mM in DMSO |
| CAS號 | 1621673-53-7 |
| 分子式 | C27H31NO3S2 |
| 分子量 | 481.67 |
| EINECS號 | |
| 相關(guān)類別 | |
| Mol文件 | 1621673-53-7.mol |
| 結(jié)構(gòu)式 |  |
化合物KY-226 性質(zhì)
| 密度 | 1.186±0.06 g/cm3(Predicted) |
|---|---|
| 儲(chǔ)存條件 | -20° |
| 溶解度 | 溶于 DMSO (>25 mg/ml)。 |
| 形態(tài) | 固體 |
| 酸度系數(shù)(pKa) | 3.91±0.40(Predicted) |
| 顏色 | 米白色 |
| 穩(wěn)定性 | 自購買之日起 1 年內(nèi)保持穩(wěn)定。 DMSO 中的溶液可在 -20° 下保存長達(dá) 3 個(gè)月。 |
| InChI | 1S/C27H31NO3S2/c1-2-3-4-8-19-33(30,31)28-27(29)26-17-13-23(14-18-26)21-32-20-22-11-15-25(16-12-22)24-9-6-5-7-10-24/h5-7,9-18H,2-4,8,19-21H2,1H3,(H,28,29) |
| InChIKey | MKXMABKUVSOEJF-UHFFFAOYSA-N |
| SMILES | O=C(NS(=O)(CCCCCC)=O)C1=CC=C(CSCC2=CC=C(C3=CC=CC=C3)C=C2)C=C1 |
| Target | Value |
|
PTP1B
(Cell-free assay) | 0.28 μM |
In human hepatoma-derived cells (HepG2), KY-226 (0.3-10 μM) increases the phosphorylated insulin receptor (pIR) produced by insulin.
KY-226 (1 μM; 24 hours; bEnd.3 cells) treatment rescues lipopolysaccharide-induced reduction of mRNA and protein levels of ZO-1. KY-226 treatment restores phosphorylation of pAkt (T308) and its downstream target forkhead box protein O1 (FoxO1) (S256) in bEnd.3 cells.
Western Blot Analysis
| Cell Line: | bEnd.3 cells stimulated with LPS |
| Concentration: | 1 μM |
| Incubation Time: | 24 hours |
| Result: | Rescued lipopolysaccharide-induced reduction of mRNA and protein levels of ZO-1. |
KY-226 (10-30 mg/kg/day; oral administration; daily; for 4 weeks; male
db/db
mice) treatment significantly reduces plasma glucose and triglyceride levels as well as hemoglobin A1c values without increasing body weight gain.
KY-226 attenuates plasma glucose elevations in the oral glucose tolerance test. KY-226 also increases pIR and phosphorylated Akt in the liver and femoral muscle.
| Animal Model: | Male db/db mice (8-11 weeks old) |
| Dosage: | 10 mg/kg and 30 mg/kg |
| Administration: | Oral administration; daily; for 4 weeks |
| Result: | Significantly reduced plasma glucose and triglyceride levels as well as hemoglobin A1c values without increasing body weight gain. |
安全信息
| WGK Germany | WGK 3 |
|---|---|
| 存儲(chǔ)類別 | 11 - 可燃固體 |
| 更新日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價(jià)格 |
|---|---|---|---|---|---|
| 2026/06/05 | HY-120327 | 抑制劑 KY-226 | 1621673-53-7 | 5mg | 600元 |
| 2026/06/05 | HY-120327 | 抑制劑 KY-226 | 1621673-53-7 | 10mM * 1mLin DMSO | 636元 |